Pfizer Inc. $PFE Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board increased its position in Pfizer Inc. (NYSE:PFE) by 150.4% in the third quarter, HoldingsChannel.com reports. The fund owned 1,098,177 shares of the biopharmaceutical company’s stock after buying an additional 659,601 shares during the period. Public Sector Pension Investment Board’s holdings in Pfizer were worth $27,982,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also added to or reduced their stakes in PFE. Curio Wealth LLC raised its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 1,098 shares during the last quarter. Harbor Asset Planning Inc. acquired a new position in Pfizer in the 2nd quarter worth approximately $29,000. Grey Fox Wealth Advisors LLC purchased a new position in Pfizer during the 3rd quarter worth approximately $29,000. Howard Hughes Medical Institute acquired a new stake in Pfizer during the 2nd quarter valued at approximately $30,000. Finally, Darwin Wealth Management LLC acquired a new stake in Pfizer during the 2nd quarter valued at approximately $32,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Up 0.4%

PFE stock opened at $27.58 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.94. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The firm has a market cap of $156.78 billion, a P/E ratio of 20.28 and a beta of 0.47. The company’s 50-day simple moving average is $25.81 and its 200-day simple moving average is $25.19.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.63 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Analyst Ratings Changes

A number of analysts have recently weighed in on PFE shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a research note on Thursday, January 22nd. Morgan Stanley cut their price target on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Bank of America lowered their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research note on Monday, December 15th. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price target for the company. in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $28.00.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.